David Hong

Trials

Studies that name David Hong as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 17:08 UTC. Open this list on ClinicalTrials.gov

• Ph1/Ph2
  NCT07843550 · A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy

  M.D. Anderson Cancer Center · not yet recruiting · Solid Tumor · principal investigator
• Ph3
  NCT06059846 · A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

  Spero Therapeutics · completed · Urinary Tract Infection, Acute Pyelonephritis · study director
• Ph1/Ph2
  NCT05703854 · Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

  M.D. Anderson Cancer Center · suspended · Advanced Renal Cell Carcinoma, Advanced Mesothelioma, Advanced Osteosarcoma · principal investigator
• Ph1
  NCT04044859 · ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

  USWM CT, LLC · active not recruiting · Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ) · principal investigator
• Ph1
  NCT03132922 · MAGE-A4ᶜ¹º³²T for Multi-Tumor

  USWM CT, LLC · active not recruiting · Urinary Bladder Cancer, Melanoma, Head and Neck Cancer · principal investigator
• Ph1
  NCT03098160 · Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

  Threshold Pharmaceuticals · unknown · Pancreatic Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck · principal investigator
• Ph1
  NCT02989064 · MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

  Adaptimmune · completed · Urothelial Carcinoma, Head and Neck Cancer, Melanoma · principal investigator
• Ph1/Ph2
  NCT02499328 · Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

  AstraZeneca · completed · Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck · principal investigator
• Ph1
  NCT02118987 · Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization

  Dana-Farber Cancer Institute · completed · Drug Allergy · principal investigator
• Ph1
  NCT00903708 · LY2275796 in Advanced Cancer

  M.D. Anderson Cancer Center · completed · Advanced Cancers · study chair
• Ph1
  NCT00458731 · Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

  National Cancer Institute (NCI) · completed · Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma · principal investigator
• Ph1
  NCT00244972 · Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer

  National Cancer Institute (NCI) · completed · Advanced Malignant Neoplasm · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 17:08 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 6 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Paul Calabresi Clinical Oncology Award
  K12CA088084 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2023 to 2026 · $476,200 awarded in 2026
  Same name and institution; not confirmed by an ID
• 12 Clinical and Translational Research Center
  P30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2022 to 2025 · $379,325 awarded in 2025
  Grant number is on one of their registry trials
• Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy
  R01CA242565 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2019 to 2025 · $218,645 awarded in 2025
  Same name and institution; not confirmed by an ID
• Therapeutic Strategies for Patients With BRAF Mutant Colorectal Cancer
  R01CA187238 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2014 to 2018 · $332,000 awarded in 2018
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Phase I Studies of Targeted Anti-Cancer Therapies
  U01CA062461 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI James C Yao · fiscal years 1994 to 2013
  Named on NCT00458731, NCT00244972